Main Article Content
Diabetes mellitus is a serious public health problem, S. aureus and MRSA are the most common bacteria isolated from ulceration of diabetic patients. The aim of the study was to estimation rate of S. aureus and MRSA carrier in diabetes type-2 and determine the antimicrobial effect of Gliotoxin on the previous bacterial carriage in type-2 diabetes. The study was conducted on 450 diabetics' patients, attended the outpatients clinic in Baquba Teaching Hospital, their ages ranged from 15-65years, with mean age of 36.15, and 150 healthy group, who were randomly selected, during the period from May 2016 to April 2017, patients were classified into two groups according to the type of diabetes, group1 included: 184 with type1-diabetes, and group2: included 266 with type2-diabetes, 97 patients with foot ulcers. Swabs were taken from anterior nares, toe and axillae for each diabetic patient type-2, identified based on standard bacteriological methods. Using the Kirby -Bauer method for detection the antibacterial effect of Gliotoxin. The results showed rates of the bacterial carriage in anterior nares of type-2diabetic patients without complications were (11.4%), (4.4%), respectively for S. aureus and MRSA, in type-2 diabetes with complications were (8.6%), (2.1%) respectively for S. aureus and MRSA. In the toe of type-2diabetic patients without complications were (6.7%), (2.5%) respectively for S. aureus and MRSA. In with complications were (9.2%), (5%) respectively. In the axillae of diabetic patients, type-2 without complications was (5.5%), (4.5%) respectively. Aspergillus fumigatus Gliotoxin was effective against bacterial carriage in diabetes type-2 with the foot ulcer, for S. aureus inhibition diameter was (20.50, 16.40, 12.20) mm for different concentrations of Gliotoxin, to MRSA was (8.25, 6.1, 4.20) mm. Increasing rate of S. aureus and MRSA carrier in diabetic patient's type-2 which lead to a significantly increased risk of bacterial infections. Gliotoxin was effective as an antibacterial agent against S. aureus and MRSA in type-2diabetis with the foot ulcer.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.